Why is Hester Bios falling/rising?

Current Market Performance and Price Movement

On 08 Dec, Hester Biosciences witnessed a notable decline in its share price, closing at ₹1,610, down ₹39 from the previous session. The stock underperformed its sector by 1.08% and touched an intraday low of ₹1,585.05, marking a 3.88% drop during the trading day. The weighted average price indicates that a larger volume of shares traded closer to the day’s low, signalling selling pressure. Furthermore, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish trend in the short to medium term.

Investor Participation and Liquidity

Interestingly, investor participation has been rising, with delivery volumes on 05 Dec increasing by 35.87% compared to the five-day average. This heightened activity, however, has not translated into price gains, indicating that the increased volume may be driven by selling rather than buying interest. The stock remains sufficiently liquid for modest trade sizes, supporting active market participation despite the downward price movement.

Long-Term Returns and Relative Performance

Over the past year, Hester Biosciences has delivered a disappointing total return of -36.61%, significantly lagging behind the Sensex’s 4.15% gain. Year-to-date, the stock is down 32.71%, while the benchmark index has risen by 8.91%. Even over longer horizons, the stock has underperformed; its three-year return stands at -12.73% compared to the Sensex’s robust 36.01%, and over five years, it trails the benchmark by nearly 95 percentage points. This persistent underperformance highlights structural challenges facing the company and dampens investor confidence.

Financial Fundamentals and Valuation Concerns

Despite reporting positive results for six consecutive quarters, including the highest operating cash flow of ₹64.51 crores and a return on capital employed (ROCE) of 10.91% in the half-year period, the company’s long-term fundamentals remain weak. Operating profits have grown at a negligible compound annual growth rate (CAGR) of -0.36% over the last five years, signalling stagnation. The company’s ability to service debt is limited, with a high Debt to EBITDA ratio of 3.73 times, raising concerns about financial leverage and risk.

Moreover, the average ROCE of 9.10% indicates low profitability relative to the capital employed, which is further reflected in the company’s expensive valuation metrics. With a ROCE of 7.7 and an enterprise value to capital employed ratio of 2.9, the stock is considered overvalued relative to its earnings power. Although the stock trades at a discount compared to peers’ historical valuations, this has not been sufficient to attract significant institutional interest, as domestic mutual funds hold no stake in the company. This absence of mutual fund participation may suggest scepticism about the company’s growth prospects or valuation at current levels.

Profit Growth Versus Market Sentiment

Interestingly, while the stock price has declined sharply over the past year, the company’s profits have risen by 86.8%, resulting in a low price-to-earnings-growth (PEG) ratio of 0.4. This disparity between profit growth and share price performance may indicate that investors remain cautious due to concerns over the company’s debt levels, valuation, and long-term growth trajectory. The disconnect also suggests that the market is pricing in risks that could impede the company’s ability to sustain profit growth or convert it into shareholder returns.

Conclusion: Why Hester Bios is Falling

In summary, Hester Biosciences’ share price decline on 08 Dec and its broader underperformance can be attributed to a combination of weak long-term fundamentals, high leverage, and expensive valuation metrics. Despite recent positive quarterly results and improving cash flows, the company’s stagnant operating profit growth and low return on capital employed have weighed heavily on investor sentiment. The stock’s persistent underperformance relative to the Sensex and its sector, coupled with the lack of institutional backing, further dampen enthusiasm. While profit growth has been strong, market participants appear cautious about the sustainability of this trend given the company’s financial structure and valuation concerns. These factors collectively explain the downward pressure on Hester Biosciences’ stock price in the current market environment.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →